Table 2.
Demographics and clinical data
| Demographics | Total (n=77) | HIV-negative (n=43) | HIV-positive (n=34) | p |
|---|---|---|---|---|
| No. (%) | No. (% of HIV-negative) | No. (% of HIV-positive) | ||
| Male sex | 38 (49) | 21 (49) | 17 (50) | 0.92 |
| Age, years, median (IQR) | 31 (25–43) | 27 (24–43) | 36 (30–43) | 0.03 |
| <30 | 32 (42) | 24 (56) | 8 (24) | 0.013 |
| 30–50 | 37 (48) | 15 (35) | 22 (65) | |
| >50 | 8 (10) | 4 (9) | 4 (12) | |
| Stage | ||||
| 1 | 5 (6) | 1 (2) | 4 (12) | 0.089 |
| 2 | 19 (25) | 14 (33) | 5 (15) | |
| 3 | 7 (9) | 5 (12) | 2 (6) | |
| 4 | 46 (60) | 22 (52) | 24 (71) | |
| Blood results, median (IQR) | ||||
| Haemoglobin, g/dL, n=77 | 10.8 (8.9–12.4) | 10.8 (8.9–12.6) | 10.6 (8.9–12.3) | 0.45 |
| Platelet, cells×109/L, n=73 | 398 (215–494) | 460 (314–568) | 270 (199–424) | 0.005 |
| Total white cell count, cells×109/L, n=77 | 9.9 (6.4–14.7) | 13.7 (9.3–16.6) | 6.5 (4.3–9.0) | <0.01 |
| Lymphocyte count, cells×109/L, n=65 | 1.43 (0.8–2.2) | 1.69 (1.4–2.6) | 1.01 (0.7–1.9) | 0.018 |
| Lactate dehydrogenase, IU/L, n=72 | 470 (352–609) | 477 (365–631) | 437 (352–585) | 0.5 |
| ESR, mm/h, n=55 | 78 (39–122) | 78 (32–107) | 83 (46–127) | 0.362 |
| Albumin, g/L, n=74 | 37 (27–41) | 37 (32–42) | 36 (24–39) | 0.1 |
| IPS ≥4 (high risk) | 26 (34) | 14 (33) | 12 (35) | 0.8 |
| EBV positive | 39 (51) | 6 (14) | 33 (97) | <0.01 |
| HL subtype | ||||
| Nodular sclerosing | 56 (73) | 38 (88) | 18 (53) | 0.003 |
| Mixed cellularity | 10 (13) | 2 (5) | 8 (24) | |
| Lymphocyte rich | 0 (0) | 0 | 0 (0) | |
| Lymphocyte depleted | 2 (3) | 1 (2) | 1 (3) | |
| HL unspecified | 9 (12) | 2 (5) | 7 (21) | |
| Treatment | ||||
| Primary treatment | ||||
| ABVD chemotherapy +/− radiation | 75 (97) | 43 (57) | 32 (43) | 0.32 |
| Died before chemo | 2 (3) | 0 (0) | 2 (100) | 0.46 |
| Secondary treatment | ||||
| Other therapy with curative intent (i.e., DHAP, IGEV or ICE) | 10 (16) | 9 (29) | 1 (3) | 0.04 |
| Autologous stem-cell transplantation | 5 (8) | 5 (16) | 0 | 0.08 |
Data are median (interquartile range) or n/N(%).
DHAP, dexamethasone, high dose ara-C, cisplatin; EBV, Epstein–Barr virus; ESR, erythrocyte sedimentation rate; HL, Hodgkin lymphoma; ICE, ifosfamide, carboplatin, etoposide; IGEV, ifosfamide, gemcitabine, vinorelbine; IPS, International Prognostic Score; IQR, interquartile range.